Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.

CONCLUSIONS: Paired ovarian cancer samples demonstrate stable genomic alterations across time. However, discordance was observed for some genes used as eligibility criteria for molecularly targeted clinical trials. Repeat tumor testing may be useful in cases where eligibility for such trials is deemed important after consideration of testing costs and potential clinical benefit.
PMID: 31703812 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - November 4, 2019 Category: Cancer & Oncology Authors: Fehniger JE, Berger AA, Juckett L, Elvin J, Levine DA, Zajchowski DA Tags: Gynecol Oncol Source Type: research